Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$49 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$-453 Mln
ROE
-2.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
-3.9
Div. Yield
0 %
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
4,048,930
CFO
$-456.31 Mln
EBITDA
$-419.61 Mln
Net Profit
$-714.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aeglea Bio Therapeutics Inc (AGLE)
| 30.2 | 30.2 | 158.9 | 116.5 | -45.8 | -33.8 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Aeglea Bio Therapeutics Inc (AGLE)
| 88.5 | -90.5 | -39.6 | 3.0 | 2.0 | 38.2 | 24.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol... modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Read more
Chief Operating Officer
Dr. Leslie S. Sloan Ph.D.
Chief Operating Officer
Dr. Leslie S. Sloan Ph.D.
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aeglea Bio Therapeutics Inc (AGLE) is $27.60 (NASDAQ) as of 30-Jan-2024 09:30 EDT. Aeglea Bio Therapeutics Inc (AGLE) has given a return of -45.84% in the last 3 years.
Since, TTM earnings of Aeglea Bio Therapeutics Inc (AGLE) is negative, P/E ratio is not available.
The P/B ratio of Aeglea Bio Therapeutics Inc (AGLE) is 0.35 times as on 30-Jan-2024, a 91 discount to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.05
|
0.09
|
|
2021
|
-0.48
|
0.37
|
|
2020
|
-0.64
|
0.37
|
|
2019
|
-0.33
|
0.42
|
|
2018
|
-0.40
|
0.27
|
The 52-week high and low of Aeglea Bio Therapeutics Inc (AGLE) are Rs -- and Rs -- as of 05-Apr-2026.
Aeglea Bio Therapeutics Inc (AGLE) has a market capitalisation of $ 49 Mln as on 30-Jan-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Aeglea Bio Therapeutics Inc (AGLE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.06
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.